GE HealthCare Technologies Inc.'s Stock Analysis

GE HealthCare Technologies Annual Meeting Voting Results Announced

GE HealthCare Technologies held its annual stockholders' meeting on May 7, 2026, where stockholders elected eight directors to serve one-year terms until the 2027 annual meeting. The meeting also included approval of the named executive officers' compensation and the ratification of Deloitte & Touche LLP as the independent auditor for the fiscal year ending December 31, 2026.

In addition to the voting results, the Board of Directors appointed Rodney F. Hochman as the independent lead director and Anne T. Madden as the chairperson of the Nominating and Governance Committee effective May 7, 2026. These appointments may influence the governance structure and oversight of the company moving forward.

May 11, 2026 16:51:39

GE HealthCare Reports Q1 2026 Financial Results and Guidance

GE HealthCare Technologies announced its first quarter 2026 financial results, reporting revenues of $5.1 billion, a 7.4% increase year-over-year, with organic revenue growth of 2.9%. Total orders rose by 1.1% organically, with a book-to-bill ratio of 1.07 and a backlog of $21.8 billion. The company experienced a net income margin of 7.6% and diluted earnings per share of $0.85, both lower compared to the previous year, largely due to a supplier issue and increased costs in memory chips, oil, and freight.

For the full year 2026, GE HealthCare has reaffirmed its organic revenue growth guidance of 3.0% to 4.0%, while adjusting its profit outlook downward due to inflation impacts. The company expects adjusted earnings per share to range between $4.80 and $5.00, reflecting a growth of 4.6% to 9.0% year-over-year. Additionally, GE HealthCare reported cash flow from operating activities of $290 million and free cash flow of $112 million, along with a quarterly dividend declaration of $0.035 per share.

Apr 29, 2026 06:25:24

GE HealthCare Appoints Kevin Lobo to Board of Directors

GE HealthCare Technologies has appointed Kevin A. Lobo, the Chair and CEO of Stryker Corporation, to its Board of Directors effective March 13, 2026. Lobo brings over 25 years of experience in medical technology and leadership, which the company anticipates will enhance its strategic priorities and growth initiatives. His term will last until the 2026 Annual Meeting of Stockholders, and he will also serve on the Talent, Culture, and Compensation Committee.

Additionally, Risa Lavizzo-Mourey and Tomislav Mihaljevic will not seek re-election to the Board at the upcoming Annual Meeting due to other commitments. Their departures are not attributed to any disagreements regarding the company's operations. GE HealthCare continues to focus on delivering advanced medical technologies and innovative solutions to improve patient care, operating as a $20.6 billion business with approximately 54,000 employees.

Mar 17, 2026 09:14:16

GE HealthCare Technologies Secures $0.5 Billion Credit Facility

On February 26, 2026, GE HealthCare Technologies Inc. entered into a new 364-Day Revolving Credit Agreement with JPMorgan Chase Bank, providing a senior unsecured revolving credit facility of $0.5 billion. This agreement replaces the previous credit facility from March 2025, which was terminated on the same date. The new facility will mature on February 25, 2027, and offers various interest rate options based on different benchmarks, including SOFR and EURIBOR rates.

The New Revolving Credit Agreement includes customary covenants that restrict the company's ability to incur additional liens and debt, as well as events of default related to payment failures and other financial conditions. These terms are designed to manage the company's financial obligations and maintain creditworthiness, which may impact investor confidence and stock performance.

Feb 27, 2026 16:15:34

GE HealthCare Reports Q4 and FY 2025 Financial Results

GE HealthCare Technologies announced its financial results for the fourth quarter and full year ended December 31, 2025. In Q4, the company achieved a revenue of $5.7 billion, reflecting a 7.1% increase, with organic revenue growth of 4.8%. The net income margin was reported at 10.3%, with diluted earnings per share (EPS) of $1.29. For the full year, total revenue reached $20.6 billion, up 4.8%, and diluted EPS increased to $4.55, marking a growth of $0.21 compared to the previous year. The company also reported strong cash flow from operating activities of $2.0 billion for the year.

Additionally, GE HealthCare highlighted its operational resilience with a record backlog and successful capital deployment strategies, including a $1.0 billion share repurchase program. The company announced its acquisition of Intelerad, aimed at enhancing its cloud-enabled enterprise imaging capabilities. Looking ahead, GE HealthCare provided guidance for 2026, projecting organic revenue growth of 3.0% to 4.0% and adjusted EPS in the range of $4.95 to $5.15, indicating a potential growth in earnings. The company’s solid financial position is supported by $4.5 billion in cash and equivalents and access to $3.5 billion in credit facilities.

Feb 04, 2026 06:25:33

GE HealthCare Secures $750 Million Term Loan and Issues Notes

GE HealthCare Technologies Inc. has entered into a three-year senior unsecured term loan credit facility amounting to $750 million, with a maturity date set for December 12, 2028. This loan will be available for a single borrowing, subject to certain conditions, and features an interest rate that can be based on either an alternate base rate or term SOFR rate. The agreement includes covenants that limit the company's ability to incur additional debt and other financial obligations.

In addition to the term loan, GE HealthCare issued $600 million in 4.150% Senior Notes due December 15, 2028, and $650 million in 4.950% Senior Notes due December 15, 2035. The proceeds from these notes, along with the term loan and existing cash, will be used to finance the acquisition of Intelerad Medical Systems. The notes are senior unsecured obligations and will pay interest semi-annually, starting in 2026.

Dec 15, 2025 17:02:44

GE HealthCare Technologies Announces $1.25 Billion Notes Offering

GE HealthCare Technologies Inc. has launched an underwritten offering totaling $600 million in 4.150% Notes due December 15, 2028, and $650 million in 4.950% Notes due December 15, 2035. The offering is part of a registration statement filed with the SEC and is expected to close around December 15, 2025, pending customary conditions.

The company has entered into an Underwriting Agreement with Goldman Sachs & Co. LLC and BNP Paribas Securities Corp. as underwriters for this offering. Further details about the Underwriting Agreement are available in the accompanying exhibit, which is incorporated by reference.

Dec 02, 2025 16:55:21

GE HealthCare Reports Q3 2025 Financial Results and Guidance

GE HealthCare Technologies Inc. announced its financial results for the third quarter of 2025, reporting a revenue of $5.1 billion, reflecting a 6% increase year-over-year. Organic revenue growth was recorded at 4%, driven by strong performance in Europe, the Middle East, Africa, and the U.S. The company reported a net income of $446 million, with a diluted earnings per share (EPS) of $0.98. The net income margin decreased to 8.7% from 9.7% in the previous year, primarily impacted by tariff expenses, while adjusted EPS was $1.07, down from $1.14 year-over-year. Cash flow from operating activities was $593 million, with free cash flow at $483 million, both showing a decline compared to the previous year due to tariff impacts.

In its updated guidance for 2025, GE HealthCare raised the lower end of its adjusted EPS forecast to a range of $4.51 to $4.63, while reaffirming its other financial targets. The company expects organic revenue growth of approximately 3% year-over-year and an adjusted EBIT margin of 15.2% to 15.4%. Tariff impacts are anticipated to affect adjusted EBIT by approximately $265 million and adjusted EPS by $0.45. GE HealthCare continues to focus on innovation and enhancing its product offerings, including recent advancements in imaging solutions and AI technology.

Oct 29, 2025 06:25:26

GE HealthCare Reports Q2 2025 Financial Results and Guidance

GE HealthCare Technologies reported its financial results for the second quarter of 2025, showing a revenue increase of 3% year-over-year, reaching $5.0 billion. The company's net income rose to $486 million, with a net income margin of 9.7%, compared to 8.9% in the previous year. Diluted earnings per share (EPS) increased to $1.06 from $0.93. The company also reported a significant improvement in cash flow from operating activities, totaling $94 million, compared to a loss of $119 million in the prior year, with free cash flow at $7 million, up from $(182) million. Additionally, GE HealthCare raised its full-year 2025 guidance, anticipating organic revenue growth of approximately 3% and adjusted EPS in the range of $4.43 to $4.63.

The company highlighted a strong demand for its products across various segments, particularly in the U.S. and Europe, the Middle East, and Africa. GE HealthCare's total orders increased by 3% organically year-over-year, and the book-to-bill ratio stood at 1.07 times. The company also emphasized its strategic collaborations and innovations in medical technology, including advancements in AI-enabled devices and new approvals for its radiopharmaceutical products. Tariff impacts were noted in the updated guidance, reflecting ongoing changes in trade policy, which could affect future financial performance.

Jul 30, 2025 06:25:33

GE HealthCare Technologies Reports Board Member Resignation

On July 23, 2025, Lloyd W. Howell, Jr. resigned from the Board of Directors of GE HealthCare Technologies Inc., effective immediately. The company clarified that Mr. Howell's departure was not due to any disagreements regarding its operations, policies, or practices.

This change in the Board of Directors may have implications for the company's governance and strategic direction. Investors may want to monitor any further developments related to the Board and the potential impact on company performance.

Jul 24, 2025 16:33:29